Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.
David Reese to retire from Amgen
Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a

